Inhibrx Biosciences (INBX) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$153.1 million.
- Inhibrx Biosciences' Enterprise Value rose 2201.98% to -$153.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.1 million, marking a year-over-year increase of 2201.98%. This contributed to the annual value of -$152.6 million for FY2024, which is 4509.43% up from last year.
- Latest data reveals that Inhibrx Biosciences reported Enterprise Value of -$153.1 million as of Q3 2025, which was up 2201.98% from -$186.6 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Enterprise Value registered a high of -$152.6 million during Q4 2024, and its lowest value of -$277.9 million during Q4 2023.
- Its 3-year average for Enterprise Value is -$201.4 million, with a median of -$196.3 million in 2024.
- As far as peak fluctuations go, Inhibrx Biosciences' Enterprise Value skyrocketed by 4509.43% in 2024, and later surged by 1776.11% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Enterprise Value stood at -$277.9 million in 2023, then surged by 45.09% to -$152.6 million in 2024, then dropped by 0.33% to -$153.1 million in 2025.
- Its Enterprise Value stands at -$153.1 million for Q3 2025, versus -$186.6 million for Q2 2025 and -$216.5 million for Q1 2025.